Table 1.
Participant characteristics
| BioFINDER-2 | Knight ADRC | |||||
|---|---|---|---|---|---|---|
| All (n = 1,422) | Cognitively unimpaired (n = 720) | Cognitively impaired (n = 702) | All (n = 337) | Cognitively unimpaired (n = 287) | Cognitively impaired (n = 50) | |
| Age, years | 69.3 (10.6) | 66.3 (12.1) | 72.3 (7.9) | 69.8 (8.3) | 69.0 (8.3) | 74.6 (6.5) |
| Women, n (%) | 708 (49.8%) | 393 (54.6%) | 315 (44.9%) | 175 (51.9%) | 155 (54.0%) | 20 (40.0%) |
| APOE-ε4 carriers, n (%)a | 659 (51.5%) | 278 (47.8%) | 381 (54.6%) | 128 (38.0%) | 101 (35.2%) | 27 (54.0%) |
| Years of educationb | 12.7 (3.9) | 12.9 (3.6) | 12.4 (4.2) | 16.4 (2.4) | 16.5 (2.3) | 15.6 (2.6) |
| Race (Black/White/Other), n | N.A. | N.A. | N.A. | 24/308/5 | 24/259/4 | 0/49/1 |
| MMSEc | 26.7 (3.9) | 28.9 (1.2) | 24.4 (4.4) | 28.8 (2.1) | 29.3 (1.1) | 26.1 (3.7) |
| Aβ PET, Centiloidsd | 19.2 (41.8) | 7.99 (31.9) | 45.0 (49.7) | 25.0 (35.6) | 17.3 (27.2) | 69.3 (44.8) |
| Aβ PET positive, n (%)d | 258 (25.8%) | 107 (15.3%) | 151 (49.7%) | 85 (25.2%) | 48 (16.7%) | 37 (74.0%) |
| Tau PET, SUVRe | 1.36 (0.47) | 1.18 (0.17) | 1.56 (0.59) | 1.20 (0.19) | 1.16 (0.09) | 1.47 (0.35) |
| Tau PET positivee | 355 (25.0%) | 49 (6.8%) | 306 (43.6%) | 35 (10.4%) | 7 (2.4%) | 28 (56.0%) |
| AD diagnosis, n (%) | 346 (24.3%) | 0 (0%) | 346 (49.3%) | 50 (14.8%) | 0 (0%) | 50 (100%) |
| Severity of cognitive impairment (CU/MCI/dementia) | 720/366/336 | 720/0/0 | 0/366/336 | 287/37/13 | 287/0/0 | 0/37/13 |
All measures represent mean (s.d.) unless otherwise stated. Percentages are calculated from the sample available for each variable. Aβ PET positivity was defined as Centiloids ≥ 37. Tau PET positivity was defined using previously validated in-house thresholds (SUVR > 1.32 for both cohorts). Race was not collected in the BioFINDER-2 cohort.
a: 143 participants missing in BioFINDER-2
b: 31 participants missing in BioFINDER-2
c: 1 participant missing in BioFINDER-2
d: 421 participants missing in BioFINDER-2
e: 54 participants missing in BioFINDER-2
f: 432 participants missing in BioFINDER-2
CU, cognitively unimpaired; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; N.A., not applicable; SUVR, standardized uptake value ratio.